List view / Grid view
14 September 2015 | By Victoria White
The new laboratory, opened in Cambridge, will focus on the discovery and development of novel biologic cancer treatments and diagnostics...
14 September 2015 | By Victoria White
The potential new antibiotics are unlike contemporary antibiotics because they contain iridium, a silvery-white transition metal...
14 September 2015 | By Victoria White
WIPO Re:Search provides access to the intellectual property of certain pharmaceutical compounds, technologies, know-how and data for R&D activities around TB and malaria...
11 September 2015 | By Victoria White
Researchers have developed a new method for studying the targets and effects of cancer drugs using data from discovery mass spectrometry experiments...
11 September 2015 | By Victoria White
The new technique could cut the potential for side effects and help usher kinase inhibitors past strict regulatory hurdles...
11 September 2015 | By Victoria White
Gencia and Takeda aim to jointly research and develop two preclinical drug candidates, one each in the areas of inflammation and oncology...
10 September 2015 | By Victoria White
The SAS1B protein appears only on egg cells and cancer cells, and could serve as a target for tiny tracking probes created using monoclonal antibodies...
8 September 2015 | By Victoria White
AMRA will collaborate with Pfizer to help provide a better understanding of the relationship between body composition and risk for obesity related diseases...
8 September 2015 | By Victoria White
Addex Therapeutics has granted an option to license its metabotropic glutamate receptor subtype 3 (mGlu3 receptor) programme to Pierre Fabre...
8 September 2015 | By Victoria White
The funding will enable ReViral to progress its lead drug candidate, RV521, into proof of concept clinical trials and to continue the development of a novel series of antiviral inhibitors...
4 September 2015 | By Oxford Global
Production is now complete for the 2nd Annual Drug Discovery USA Congress taking place on the 29th & 30th of October 2015 in Boston, USA...
3 September 2015 | By Victoria White
Horizon and Redx have announced a new research collaboration to progress Redx’s pan-RAF inhibitor programme, for out-licensing in oncology indications...
1 September 2015 | By Nick Jackson
Dr Koslowski brings over 15 years’ experience across biopharmaceutical research and development, specialising in drug target discovery and clinical validation...
20 August 2015 | By Victoria White
Janus Biotherapeutics has entered into a collaboration with Roche for the development of a small molecule toll-like receptor (TLR) inhibitor...
19 August 2015 | By Victoria White
Scientists have developed a potentially better and more accurate high-throughput screening technique and have used it to identify 24 drug candidates...
